Page tree

Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

Date

09/xx/2016

1800 UTC

 

GoToMeeting Details

https://global.gotomeeting.com/join/374912925

 Use your microphone and speakers (VoIP) - a headset is recommended. Or, call in using your telephone.

Dial +1 (872) 240-3212
Access Code: 374-912-925
Audio PIN: Shown after joining the meeting

Meeting ID: 374-912-925

Attendees

Chair:

AG Members

  • Observers

 

Apologies

Objectives

  • Obtain consensus on agenda items

Discussion items

ItemDescriptionOwnerNotesAction
1Call to order and role callJCA

 

 

2Approval of 20160627 minutesJCA 
  •  Approve minutes from 06/27/2016

3  

 

 

 
4 Assessment instrument responsesJCA

Policy on addition of assessment tool responses to the International edition.

IHTSDO currently accepts "names" of assessment instruments and staging scales; however, there is nothing in the editorial guide that specifically addresses the responses to assessment instrument questions. As many of these are extremely context dependent, being tied specifically to the particular instrument, what should be the policy of IHTSDO to requests to add assessment instrument responses to the International release.

Example: Requests to add responses to Tinetti balance assessment tool

 

 

 
5    
6    
7Extend the range of PATHOLOGICAL PROCESS (1)JCA

During the congenital disease revision project, it was determined that the differentiating feature of Developmental anomalies vs. acquired anomalies was the process/origin of the anomaly. Historicvally this resulted in the creation of the Developmental anomaly (morphologic abnormality) subhierarchy which essentially duplicates content within the Morphologically abnormal structure hierarchy with only the addition of "Congenital". This has caused substantial issues with the Congenital disease revision project. The following is proposed:

  1. In order to inactivate the “Congenital X (morphologic abnormality)” subhierarchy, must have a way to identify the non-congenital morphologies as a result of a developmental process.  The new proposed model is that the range for PATHOLOGICAL PROCESS be expanded to include “Pathological development process”(existing concept not in approved range).  This relationship would only be used where the abnormality is the direct result of abnormal development.  The primary use would be for children of “Congenital malformation”.
  2. Congenital deformities, which may not be the result of a developmental process (mechanical or traumatic), would not have the PATHOLOGICAL PROCESS relationship added.
  3. Concepts that currently have the ASSOCIATED MORPHOLOGY = Developmental anomaly would be replaced with a relationship group of ASSOCIATED MORPHOLOGY =  “Morphologically abnormal structure” and PATHOLOGICAL PROCESS = “Pathological developmental process”.

This has been preliminarily tested and no unexpected, untoward or erroneous inferences were identified.

 
8Extend the range of PATHOLOGICAL PROCESS (2)JCA

Idiopathic disease is currently a primitive concept that is inconsistently used. As a working definition, Idiopathic = "relating to or denoting any disease or condition that arises spontaneously or for which the cause is unknown." While it is arguable that Idiopathic is a "process" per se, one could equate it to "unidentified process" that has clinical value. There are currently around 200 concepts with Idiopathic in one or more descriptions (IHTSDO-799).

Propose to test the extension of the range of PATHOLOGICAL PROCESS to include

54690008 | Unknown (origin) (qualifier value) |.
 
9Action item reviewEAG

Space Actions

 
10Potential agenda topics for Wellington meetingJCA

We are meeting for a full day in New Zealand. Need substantive topics to move forward.

AG Member travel FAQ: https://ihtsdo.freshdesk.com/support/solutions/folders/4000008052

 

  •  Solicit additional agenda topics for Face-to-face meeting
  •  Verify travel requests have been submitted
11September conference call date and time verificationJCA

JCA is traveling Sept 10-23. Meeting scheduled for Sept 26

 

 
12Additional itemsEAGInformational item: In order to support the use of qualifier values for nominal results reporting in laboratory and other clinical domains, the range of values allowed for the HAS INTERPRETATION relationship will be extended beyond << 260245000 | Findings values (qualifier value) |. The initial extension will be < 263714004 | Colors (qualifier value) |. Additional subhierarchies will be added as necessary to support specific international use cases submitted by members.

 

 

 

Meeting Files

View file
nameTinettiBalanceAssessment.pdf
height250
 

Meeting minutes

2016-08-22 Editorial Advisory Group Conference Call